SCHEMBL25801942

SCHEMBL25801942

CCCCCCCCCCCOC(=O)CCCCCN(CCOCc1ccccc1)C(=O)OC(C)(C)C

nearest known ligand 0.56

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 5/20 0.56
HDAC3 O15379 1/20 0.42
HDAC1 Q13547 1/20 0.42
HDAC2 Q92769 1/20 0.42
NCOR2 Q9Y618 1/20 0.42
PTPN1 P18031 1/20 0.41
CNR2 P34972 1/20 0.39
DNM1 Q05193 1/20 0.39
CCKBR P32239 1/20 0.39
LTA4H P09960 1/20 0.39
DGKA P23743 1/20 0.39
ALDH1A1 P00352 1/20 0.38
CYP3A4 P08684 1/20 0.38
TSHR P16473 1/20 0.38
MAPK1 P28482 1/20 0.38
TDP1 Q9NUW8 1/20 0.38
PRSS1 P07477 1/20 0.38
PRSS2 P07478 1/20 0.38
PRSS3 P35030 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25801927 0.91 L3MBTL1 (0.63) L3MBTL1HDAC3HDAC1HDAC2NCOR2
SCHEMBL21068526 0.85 L3MBTL1 (0.64) L3MBTL1HDAC3HDAC1HDAC2NCOR2
SCHEMBL4344803 0.82 L3MBTL1 (0.58) L3MBTL1HDAC3HDAC1HDAC2NCOR2
SCHEMBL27783862 0.82 DGKA (0.54) L3MBTL1PTPN1DGKAALDH1A1CYP3A4
SCHEMBL14239718 0.81 DGKA (0.56) DNM1DGKAALDH1A1TSHRPRSS1
SCHEMBL3664799 0.80 MEN1 (0.43) L3MBTL1HDAC3HDAC1HDAC2NCOR2
SCHEMBL14240476 0.79 DNM1 (0.60) HDAC1HDAC2DNM1DGKAALDH1A1
SCHEMBL11612631 0.78 DGKA (0.60) L3MBTL1PTPN1DNM1DGKAALDH1A1
SCHEMBL11610429 0.78 DGKA (0.60) L3MBTL1PTPN1DNM1DGKAALDH1A1
SCHEMBL17450365 0.77 DGKA (0.55) L3MBTL1PTPN1CNR2DGKAALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4736848-A1 PHARMACEUTICAL COMPOSITION CONTAINING CATIONIC LIPID AND USE THEREOF Shanghai Regenelead Therapies Co., Ltd. (CN) 2026-05-06 EP disclosed
US-20250064750-A1 LIPID AND COMPOSITION USED FOR DELIVERY JIANGSU HENGRUI PHARMACEUTICALS CO., LTD. (CN) 2025-02-27 US disclosed
WO-2025002352-A1 PHARMACEUTICAL COMPOSITION CONTAINING CATIONIC LIPID AND USE THEREOF 上海瑞宏迪医药有限公司 2025-01-02 WO disclosed
EP-4458806-A1 LIPID AND COMPOSITION USED FOR DELIVERY Jiangsu Hengrui Pharmaceuticals Co., Ltd. (CN) 2024-11-06 EP disclosed
WO-2023125738-A1 LIPID AND COMPOSITION USED FOR DELIVERY 江苏恒瑞医药股份有限公司 2023-07-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250064750-A1 LIPID AND COMPOSITION USED FOR DELIVERY H1-0, H1-2, H1-3 L3MBTL1 511/4885HDAC3 136/4885HDAC1 34/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.